{Reference Type}: Journal Article
{Title}: NCCN Guidelines® Insights: Breast Cancer Screening and Diagnosis, Version 1.2023.
{Author}: Bevers TB;Niell BL;Baker JL;Bennett DL;Bonaccio E;Camp MS;Chikarmane S;Conant EF;Eghtedari M;Flanagan MR;Hawley J;Helvie M;Hodgkiss L;Hoyt TL;Ivanovich J;Jochelson MS;Kulkarni S;Lancaster RB;Mauer C;Maxwell J;Patel BK;Pearlman M;Philpotts L;Plecha D;Plichta JK;Shakeri S;Smith ML;Streibert CL;Strigel RM;Tumyan L;Winkler NS;Wolverton DE;Bergman MA;Kumar R;Stehman K;
{Journal}: J Natl Compr Canc Netw
{Volume}: 21
{Issue}: 9
{Year}: 2023 09
{Factor}: 12.693
{DOI}: 10.6004/jnccn.2023.0046
{Abstract}: The NCCN Guidelines for Breast Cancer Screening and Diagnosis provide health care providers with a practical, consistent framework for screening and evaluating a spectrum of clinical presentations and breast lesions. The NCCN Breast Cancer Screening and Diagnosis Panel is composed of a multidisciplinary team of experts in the field, including representation from medical oncology, gynecologic oncology, surgical oncology, internal medicine, family practice, preventive medicine, pathology, diagnostic and interventional radiology, as well as patient advocacy. The NCCN Breast Cancer Screening and Diagnosis Panel meets at least annually to review emerging data and comments from reviewers within their institutions to guide updates to existing recommendations. These NCCN Guidelines Insights summarize the panel's decision-making and discussion surrounding the most recent updates to the guideline's screening recommendations.